Eisai stock weighs oncology approval after strong first quarter

Published on 10/07/2026 at 02:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eisai stock was last at JPY 4,676 on October 6, 2026, while fiscal first-quarter EPS reached JPY 64.71. The FDA added an oncology indication in September.

Eisai, JP3160400002, Illustration mit AI erstellt.

Eisai stock (ISIN JP3160400002) was last at JPY 4,676 on the Tokyo Stock Exchange on October 6, 2026 at 3:30 p.m. JST, up 0.36 percent on the session. The latest company picture combines better-than-estimate first-quarter earnings with another regulatory expansion for its oncology portfolio.

First-quarter earnings beat estimate

For the fiscal first quarter of 2026, Eisai reported revenue of JPY 234.33 billion and GAAP earnings per share of JPY 64.71. Yahoo Finance shows the quarter's EPS estimate at JPY 55.66, putting actual EPS JPY 9.05 above consensus.

The earnings profile is profitable but not without sensitivity to execution. Net income was JPY 18.24 billion and the reported profit margin was 7.78 percent for Q1 FY27, according to Yahoo Finance.

Oncology portfolio expands

On September 24, 2026, the U.S. Food and Drug Administration approved belzutifan with Eisai's lenvatinib for adults with advanced clear cell renal cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor. The decision adds a defined post-immunotherapy setting for LENVIMA.

The FDA said the combination produced median progression-free survival of 14.6 months versus 10.6 months for cabozantinib. The objective response rate was 53 percent versus 40 percent, while the final overall-survival analysis did not reach statistical significance, according to the FDA.

Eisai's own release list also records the September 28, 2026 approval as the first approved combination of a HIF-2 alpha inhibitor and a multi-targeted VEGFR-TKI for this patient group, according to Eisai.

Consensus stays below the share price

Valuation expectations remain divided. A September 25 analyst update kept the rating at Neutral and raised one Japanese securities firm's target from JPY 4,300 to JPY 4,400; the report also cited a Neutral consensus from 13 analysts with an average target of JPY 4,445, according to Yahoo Finance Japan. That average target is JPY 231 below the October 6 price.

The market is also pricing a wide range of outcomes. Yahoo Finance lists a 52-week range of JPY 3,660 to JPY 5,243, with the latest price sitting JPY 567 below the high and JPY 1,016 above the low. Volume reached 1,052,800 shares on October 6, 2026.

Eisai stock heads toward November results

Yahoo Finance lists November 10, 2026 as Eisai's next earnings date. For investors, the key checkpoint is whether revenue growth and the oncology approval can offset the margin and reimbursement questions already reflected in the spread between the share price and consensus target.

Eisai stock was last at JPY 4,676 on October 6, 2026 on the Tokyo Stock Exchange. Its market capitalization was JPY 1.3 trillion, while the 52-week range stood at JPY 3,660 to JPY 5,243.